In Collaboration With

Endpoints is the biopharma and healthcare industries' trusted source for up-to-the-moment news, in-depth reporting on science and business, and coverage of the people, companies and money that drive innovation.

Global Knowledge Partner

McKinsey & Company is a global management consulting firm committed to helping organizations accelerate sustainable and inclusive growth. We work with clients across the private, public, and social sectors to solve complex problems and create positive change for all their stakeholders. We combine bold strategies and transformative technologies to help organizations innovate more sustainably, achieve lasting gains in performance, and build workforces that will thrive for this generation and the next.

Strategic Partner

Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.

Strategic Partner

Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, our team of more than 21,000 global professionals works in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind, increasing access and participation to make clinical research a care option for anyone, anywhere. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas, while our innovation ecosystem offers quality solutions to make every phase of the clinical trial process more efficient. With the people, insight and focus on operational excellence, we work With Heart^TM every day to treat patients with dignity and continuously learn from their experiences, so every trial makes a difference. This approach continues to earn us recognition industrywide, with Parexel being the recipient of the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award for advancing the clinical research profession through strong site partnerships and named “Top CRO to Work With” by investigative sites worldwide in the 2023 WCG CenterWatch Global Site Relationship Benchmark Survey.

Strategic Partner

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are focused on developing innovative medicines that transform lives and create a healthier world. Together, we are fighting for solutions to ensure patients can access and afford medicines that prevent, treat and cure disease. PhRMA member companies have invested more than $850 billion in the search for new treatments and cures over the last decade, supporting nearly five million jobs in the United States. 

Strategic Partner

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit: www.samsungbioepis.com and follow us on LinkedIn and X.

Strategic Partner

Company profile coming soon.

Lead Sponsor

Benchling is the platform where modern drug discovery and development runs. We connect experiments, data, AI, and teams across the full R&D lifecycle, from molecule design to clinical development. With built-in AI agents like Deep Research and Compose and scientific models like AlphaFold and Boltz, scientists automate lab work and design better molecules inside their daily workflows. Trusted by 1,300+ biotech companies, Benchling is bringing AI to one of the world’s most complex industries.

Lead Sponsor

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 36,000 trials and 11 million patients, Medidata, a Dassault Systèmes brand, offers industry-leading expertise, analytics-powered insights, and one of the largest clinical trial data sets. Over 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. Medidata is recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com. Follow us at @Medidata.

Lead Sponsor

TrialWire® is redefining how clinical trials recruit patients in an era where speed, precision and trust are non-negotiable. The fastest, intelligent recruitment engine, TrialWire can be activated within 24 hours to address one of drug development’s greatest constraints: patient recruitment. As timelines compress and capital efficiency becomes critical, TrialWire enables biopharmaceutical companies to identify and engage highly qualified participants with unprecedented speed. Its AI-driven platform analyses real-world digital behaviour to connect studies with people actively researching their health, supporting both early and late-phase trials. Seamlessly integrating with sponsor and CRO workflows, the platform combines advanced algorithms, AI-match screening and unified communications to deliver real-time recruitment data transparency across all sites and studies. Operating on a pay-per-enrollment, risk-share model, TrialWire aligns its success directly with that of its partners, ensuring accountability and measurable outcomes. Privacy-by-design architecture guarantees compliance with global data protection standards, including GDPR and HIPAA. With operations across North America, Europe and Asia Pacific, TrialWire helps sponsors and CROs meet development milestones, reduce execution risk and accelerate access to life-changing therapies.
www.trialwire.ai

Associate Sponsor

Evidation is redefining real-world data through direct, interactive relationships with millions of individuals. Through continuous engagement, Evidation captures longitudinal, multimodal data to provide a more complete picture of health, including patient-reported and functional outcomes, connected device data, permissioned clinical records, and biosamples. Its privacy-first platform supports a right person, right time approach to data collection, enabling faster research, stronger evidence, and better product decisions. Founded in 2012, Evidation is headquartered in California.
https://evidation.com/

Associate Sponsor

Company profile coming soon.

Associate Sponsor

IBM is a leading global hybrid cloud and AI, and business services provider, helping clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs, and gain the competitive edge in their industries. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity, and service. For more information, visit www.ibm.com.

We have a few packages remaining, get in touch today to see how you can get involved.

© Financial Times Live

FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice